Dodge & Cox Has $411.74 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Dodge & Cox grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 134.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,016,425 shares of the company's stock after acquiring an additional 1,728,605 shares during the quarter. Dodge & Cox owned 2.98% of Neurocrine Biosciences worth $411,742,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Golden State Wealth Management LLC bought a new stake in Neurocrine Biosciences in the 4th quarter valued at about $25,000. Huntington National Bank boosted its stake in shares of Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after buying an additional 97 shares during the period. Brooklyn Investment Group boosted its stake in shares of Neurocrine Biosciences by 99.1% in the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after buying an additional 115 shares during the period. Lindbrook Capital LLC increased its stake in Neurocrine Biosciences by 53.5% during the 4th quarter. Lindbrook Capital LLC now owns 373 shares of the company's stock worth $51,000 after acquiring an additional 130 shares during the period. Finally, R Squared Ltd bought a new position in Neurocrine Biosciences during the 4th quarter worth $61,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 5,844 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total value of $681,936.36. Following the completion of the sale, the director now directly owns 521,618 shares in the company, valued at approximately $60,867,604.42. This trade represents a 1.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Julie Cooke sold 1,551 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $116.78, for a total transaction of $181,125.78. Following the transaction, the insider now owns 19,544 shares in the company, valued at $2,282,348.32. This represents a 7.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 167,906 shares of company stock valued at $24,671,530 over the last 90 days. Company insiders own 4.30% of the company's stock.

Neurocrine Biosciences Trading Up 1.3 %

NBIX stock traded up $1.28 during trading on Friday, hitting $101.38. The company had a trading volume of 1,926,795 shares, compared to its average volume of 1,051,299. The stock has a market cap of $10.03 billion, a PE ratio of 30.81, a PEG ratio of 0.77 and a beta of 0.33. The business has a 50-day moving average of $108.66 and a 200-day moving average of $122.48. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences announced that its board has approved a stock buyback plan on Friday, February 21st that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to buy up to 4.2% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on NBIX. HC Wainwright reissued a "buy" rating and set a $185.00 target price on shares of Neurocrine Biosciences in a report on Friday, February 21st. Canaccord Genuity Group decreased their target price on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a "buy" rating on the stock in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a research report on Tuesday, February 11th. They issued a "hold" rating and a $138.00 target price for the company. UBS Group reduced their price target on shares of Neurocrine Biosciences from $154.00 to $137.00 and set a "buy" rating on the stock in a research report on Friday, April 4th. Finally, Bank of America lowered their price objective on shares of Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Three investment analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $161.86.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.